How Wegovy Works for Type 2 Diabetes
Wegovy (semaglutide 2.4 mg) is a glucagon-like peptide-1 receptor agonist that slows gastric emptying, reduces appetite, and improves insulin response. In the STEP 1 trial, adults with overweight or obesity and type 2 diabetes lost an average of 14.9% of body weight over 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo, with improvements in glycated hemoglobin. The FDA approved Wegovy for chronic weight management in June 2021, and subsequent trials showed cardiovascular risk reduction in patients with established heart disease and type 2 diabetes, a profile reported by Novo Nordisk and studied in trials such as SUSTAIN FORTE and STEP 2. More data on the mechanism and outcomes are available on the Novo Nordisk site.
Wegovy is not a standalone diabetes medication but an adjunct to diet and exercise. It lowers fasting glucose and reduces the need for some glucose-lowering drugs in people with type 2 diabetes. In the STEP 2 trial, semaglutide 2.4 mg reduced HbA1c by 1.4 percentage points on average versus placebo. The drug is prescribed alongside metformin, SGLT2 inhibitors, or insulin when appropriate. Coverage decisions often depend on BMI thresholds, diabetes duration, and prior treatment history, which insurers review before approval.
Clinical Results and Safety Profile
In the STEP 1 and STEP 2 studies, participants with type 2 diabetes on semaglutide 2.4 mg achieved mean weight loss of 14.9% and 1.4% HbA1c reduction respectively, with placebo arms showing 2.4% weight loss and smaller HbA1c changes. Cardiovascular outcomes data from the SUSTAIN 6 and PIONEER 6 trials showed a 26% reduction in the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke with semaglutide versus placebo in high-risk patients, including those with type 2 diabetes. The FDA label includes warnings for medullary thyroid carcinoma risk and acute pancreatitis, and common side effects include nausea, diarrhea, and decreased appetite.
Real-world data from 2024 and early 2025 show continued weight loss durability and diabetes improvement when patients stay on therapy. In U.S. commercial claims analyses, about 50% to 60% of patients with type 2 diabetes on Wegovy maintained at least 10% weight loss at 12 months when adherence was high. Discontinuation rates remain around 30% to 40% within the first year, mainly due to gastrointestinal side effects or cost barriers. The safety profile remains consistent with trial data, with low rates of serious adverse events and no new signals reported in postmarketing studies as of 2025.
Cost, Coverage, and Access in 2025
Wegovy list price in the U.S. remains around $1,300 per month as of 2025, but net prices vary by insurance, pharmacy benefit manager, and patient assistance programs. Novo Nordisk offers the Wegovy Savings Card for commercially insured patients, which can lower out-of-pocket costs to as low as $25 per fill for eligible individuals. Medicare does not currently cover Wegovy for weight management, though some Medicare Advantage plans may cover it for diabetes-related indications under specific policies. Patients without coverage often use manufacturer coupons, specialty pharmacy programs, or patient assistance foundations to reduce cost.
In 2025, Wegovy remains one of the highest-ranked GLP-1 receptor agonists for weight loss in type 2 diabetes, with coverage expanding on major formulary lists including those of CVS Caremark, Express Scripts, and OptumRx. Coverage often requires